Loss of ARHI expression is associated with tumor progression and poor prognosis, while its re-expression in cancer cells inhibits signaling through the Ras/MAPK pathway, induces p21WAF1/CIP1, and downregulates cyclin D1 [19]. Here, DIRAS3 is linked to cancer.